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Abstract
Many bacterial pathogens are becoming drug resistant faster than we can develop new antimicrobials. To address this
threat in public health, a metamodel antimicrobial cocktail optimization (MACO) scheme is demonstrated for rapid
screening of potent antibiotic cocktails using uropathogenic clinical isolates as model systems. With the MACO scheme,
only 18 parallel trials were required to determine a potent antimicrobial cocktail out of hundreds of possible combinations.
In particular, trimethoprim and gentamicin were identified to work synergistically for inhibiting the bacterial growth.
Sensitivity analysis indicated gentamicin functions as a synergist for trimethoprim, and reduces its minimum inhibitory
concentration for 40-fold. Validation study also confirmed that the trimethoprim-gentamicin synergistic cocktail effectively
inhibited the growths of multiple strains of uropathogenic clinical isolates. With its effectiveness and simplicity, the MACO
scheme possesses the potential to serve as a generic platform for identifying synergistic antimicrobial cocktails toward
management of bacterial infection in the future.
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Introduction
Infectious diseases caused by bacterial pathogens are top
causes of health complications and mortality in the world [1].
The pathogens responsible for many human infectious diseases
such as urinary tract infection, tuberculosis, gastroenteritis,
pneumonia, and wound infection sa r ep r o v e nt ob eh i g h l ya d e p t
in acquiring mechanisms of antimicrobial resistance [2,3,4]. The
rapid emergence of multidrug resistant pathogens or ‘‘super
bugs’’ is contributed by the widespread injudicious practice of
empiric antibiotic usage and infiltration of antibiotics in the food
chain, which have accelerated selection and dissemination of
resistant pathogens [5]. Consequently, clinicians have fewer
treatment options, particularly in the most needy patients. On
the other hand, the excessive cost for developing a new
antimicrobial and its short useful lifetime render a poor
investment returns. Many pharmaceutical companies have de-
emphasized their antimicrobial research programs in the past
two decades and only few large firms are currently active in
building the clinical antibiotic pipeline. As a result, the constant
need for new antibiotics has far outpaced the development of new
classes of antimicrobials by the pharmaceutical industry (2 in the
last 20 years) [5,6]. This represents a significant threat in public
health. Undoubtedly, new sources of antibiotics are highly sought
after [7].
The discovery of antibiotics has been traditionally focused on
natural products and semi-synthetic tailoring of these natural
compounds chemically. Natural substances produced by microor-
ganisms are the most important source of antibiotics. For example,
gentamicin is an aminoglycoside antibiotic targeting bacterial
ribosomes and is produced by fermentation using micromonospora.
Many plant-derived materials, such as cinnamon oils and
peppermint oils, are also natural antimicrobial agents [8,9,10].
In fact, the use of plants with antimicrobial activities for treating
wound infections was described in Chinese medicine and other
ancient cultures at least 2500 years ago [11]. After the intensive
screening of natural antibiotics in the past 50 years, recent
antibiotic research effort is migrating to newer sources of natural
antimicrobials, such as cyanobacteria and antimicrobial peptides
[12,13]. Synthetic compounds can also provide new avenues in
antimicrobials. As an example, sulfamethoxazole is a synthetic
antimicrobial that inhibits the folate biosynthetic pathway. Novel
libraries of synthetic compounds are being developed to provide
improved architectural complexity approaching that of natural
products to serve as structural scaffolds for creating new antibiotics
[14].
Combination antimicrobial therapy using synergistic antibiotic
cocktails, on the other hand, represents an appealing option for
treating bacterial infections [7]. A finely tuned mixture of drugs, in
many cases, is known to be more effective than monotherapy. A
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fight against human immunodeficiency virus, the virus that causes
acquired immune deficiency syndrome [15]. Another example is
the treatment of childhood acute lymphoblastic leukemia by the
optimization of drug cocktails based on clinical empiricism and
trial and error. Evidence for this is seen by the fact that the death
rate for acute lymphoblastic leukemia has dropped 90% in the past
25 years [16]. A key advantage of combination therapy using
synergistic, or even additive, cocktails is the reduction in drug
concentration, which minimizes the toxicity and side effects of
many antimicrobials to the host. For instance, high doses of
gentamicin can cause renal failure, and permanent losses of
equilibrioception and hearing [17,18]. Combination antimicrobial
therapy is, therefore, likely a fruitful option for the treatment of
infectious diseases caused by bacterial pathogens. As a matter of
fact, co-trimoxazole, a two-drug synergistic combination with
trimethoprim and sulphamethoxazole at a 1:5 ratio, is one of the
best selling antibiotics for the treatment of various bacterial
infections [19]. Nevertheless, a first hurdle in implementing
combination antimicrobial therapy is to identify potent cocktails
out of a large number of possible drug combinations. It is difficult
to predict synergistic activities between different antimicrobials by
studying them individually. Furthermore, the optimal dose of a
drug individually could often be different from the most effective
dose in a potent cocktail. Identifying potent cocktails out of
different concentrations of various antibiotics represent a classical
combinatorial optimization problem and the possible combina-
tions increases rapidly with the number of antimicrobials being
considered [20,21]. A systematic procedure for rapidly determin-
ing synergistic antimicrobial cocktails is, therefore, necessary to
accelerate our progress in combination antimicrobial therapy. In
addition, rapid determination of potent antimicrobial cocktails will
also improve our ability to promptly response to multidrug
resistant pathogens and biological warfare agents in emergency
situations and high-risk areas such as temporary clinics established
in response to natural and man-made disasters.
Optimization strategies in engineering and computer sciences
are well-established approaches for controlling highly complex
systems and will likely play an essential role in numerous
biomedical sciences and clinical applications [20,21,22,23,24,25].
For instance, search algorithms, which iteratively determine the
optimal solutions (drug cocktails) in the parametric spaces
(different drug combinations), can be applied for determining
synergistic drug combinations. A closed-loop optimization strategy
was demonstrated for rapid screening of antiviral drug cocktails
and identifying cytokine combinations to regulate the NF-kB using
signal transduction pathway using a stochastic search algorithm,
Gur Game [26]. A Medicinal Algorithmic Combinatorial Screen
based on the hill climbing algorithm was demonstrated for
screening anti-cancer drug cocktails [27]. A parallel search
scheme, Differential Evolution algorithm, was demonstrated for
identifying antiviral cocktails for Kaposi’s Sarcoma-associated
Herpesvirus [28]. These search algorithms, which test drug
cocktails sequentially, are especially effective for biological systems
with smooth response surfaces in the parametric space. Due to the
urgency of many infectious diseases, a metamodel antimicrobial
cocktail optimization (MACO) scheme that combines fractional
factorial design and stepwise regression is explored in this study. A
potential advantage of MACO is that experiment trails are
performed in parallel, which dramatically reduces the time
required for determining a synergistic cocktail. In general,
fractional factorial design is a statistical information-gathering
strategy and has been widely applied in engineering research and
industrial settings [21,29]. Instead of brute-force or exhaustive
search of all possible drug combinations, which are often
impractical in many situations, fractional factorial design can
dramatically reduce the number of experiments by defining trials
that capture the individual and interactive effects on the response
of a complex system. Based on the result, stepwise regression
model building procedures can then be performed to extract the
potential synergistic interactions between antibiotics.
In this study, the MACO scheme is studied for rapid screening
of antimicrobial cocktails from a pool of natural and synthetic
antimicrobials. In particular, pathogenic E. coli clinical isolates that
cause urinary tract infection were chosen as the test organism in
this study. A simplified 3-drug search experiment was first
performed to illustrate the concept of the scheme for identifying
synergistic antimicrobial cocktails. Antimicrobial cocktails were
then searched from 5 drugs or 6 drugs to evaluate its robustness in
determination of potent drug cocktails. A synergistic cocktail was
identified in the study and was evaluated independently using
several strains of E. coli clinical isolates to evaluate its general
applicability. This study will potentially form the foundation of a
statistical optimization approach for identifying synergistic anti-
microbial cocktails toward the treatment of bacterial infections.
Results
A flowchart representation of the general procedures of the
MACO scheme is shown in Figure 1. To illustrate the concept of
the MACO scheme, a simplified 3-drug screening experiment was
performed using trimethoprim (TMP), ampicillin (AMP), genta-
micin (GEN) for inhibiting the growth of an E. coli clinical isolate
(EC132). Three concentration levels for each antibiotic were
Figure 1. Flowchart representation of the metamodel antimi-
crobial cocktail optimization (MACO) scheme for identifying
potent antimicrobial cocktails. In the MACO scheme, the concen-
tration levels of a set of antibiotics are first chosen based on a pathogen
of interest. Fractional factorial design is then performed to select
experimental trials that capture the main effects and interactions of
antibiotics. Stepwise regression analysis is performed to extract the
most effective cocktail in the parametric space. If a synergistic cocktail is
identified, the cocktail can be tested for its synergistic activity. If not,
the procedure can be repeated with modifications in antibiotics and
concentration levels until a synergistic cocktail is identified.
doi:10.1371/journal.pone.0015472.g001
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zero for all three antibiotics. The highest concentrations for TMP
and GEN were chosen to be smaller than their minimum
inhibitory concentrations (MIC) since the goal of the experiment
is to identify synergistic interaction, instead of individual effects of
the antibiotics. EC132 is resistant to AMP and the concentrations
of AMP were chosen based on typical values applied in
antimicrobial susceptibility testing experiments. Figure 2b shows
the fractional factorial design of 9 trials out of the 27 tests required
in a full factorial design. The growths of EC132 under different
antibiotic combinations were measured (Figure 2c). Inspecting the
data revealed that trials 5 and 7, which had relative high
concentrations of GEN and TMP, were most effective in inhibiting
the bacterial growth. It is intuitive that GEN and TMP may work
synergistically for inhibiting bacterial growth. To systematically
determine the most potent antimicrobial combination, the data
were fed into the statistic software for stepwise regression analyses.
The analyses were performed using the fractional regression and
quadratic response surface models. In both models, the interaction
between TMP and GEN was identified to be the strongest
interaction in the antimicrobial combinations. All other factors
and interactions were discarded in the forward stepwise regression
procedure independent of the model used. The resulting
regression model is shown in Figure 2d. In other words, the
MACO analysis predicted that the TMP-GEN cocktail had the
most potent effect among all individual antibiotics and antibiotic
combinations. While the potent cocktail can be determined
directly by inspecting the data in this case, the regression analysis
in MACO is especially useful for extracting the potent interactions
with a larger number of antibiotics.
The MACO scheme was then performed for screening
antimicrobial cocktails from a larger number of antibiotics. In
addition to TMP, AMP, and GEN, sulfamethoxazole (SMX),
cinnamon oil (CIN), and peppermint oil (PEP) were considered in
the tests. Similar to the 3-drug experiment, 3 concentrations were
assigned for each antibiotic. The highest concentrations of CIN
and PEP were chosen to be both 0.02% (Figure 3a and Figure 4a),
which was 4-fold smaller than their MIC. EC132 is known to be
resistant to SMX and the highest concentration was chosen based
on the 1:19 ratio of the synergistic TMP-SMX combination,
which is recommend by the Clinical and Laboratory Standards
Institute [30]. The fractional factorial designs for 6 antibiotics
required 18 trials out of 729 (3
6) combinations (Figure 3b and
Figure 4b). The bacterial growths under these conditions are
shown in Figure 3c and Figure 4c. The results of the regression
analyses using the fractional regression and quadratic response
surface models are shown in Figure 3d and Figure 4d. In
agreement with the 3-drug experiment, TMP and GEN were
identified to have the most potent interaction in the 5-drug and 6-
durg experiments using both regression models.
In the 5-drug experiment, trials 8 and 16, which had the highest
concentrations for both TMP and GEN, were indeed highly
effective in inhibiting the growth of the bacteria. The results of the
6-drug experiment were not as intuitive as the other experiments.
In the 6-drug experiment, multiple cocktails, trials 5, 8, 9, 11, 14,
and 16, were able to effectively inhibit the growth of the
pathogens. Based on these data, one could suggest SMX-CIN,
TMP-GEN-PEP, CIN-PEP, and TMP-GEN-CIN may processes
synergistic activities. A close inspection of the data revealed TMP
is critical for inhibiting the bacterial growth based on trials 1, 2, 3
and 10 and TMP-GEN was likely to have the strongest activity
based on trials 8 and 16. It should also be note that co-
trimoxazole, the combination of TMP and SMX, is also a well-
known synergistic cocktail. Interestingly, the regression analyses
selected TMP-GEN instead of TMP-SMX as the most potent
cocktail for the E. coli clinical isolate using both models. It could be
a result of the low concentration of TMP in the experiment and
the SMX resistant property of EC132. In fact, the concentration of
Figure 2. A 3-drug experiment for demonstrating the concept of the MACO scheme. (a) Three concentration levels for each antibiotic are
assigned. (b) Fractional factorial experimental design for the three antibiotics considered in this experiment. 9 experimental trials are required. (c)
Results of antibiotic susceptibility testing on trials defined in (b). (d) Result of the regression analysis based on the factorial regression and quadratic
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GEN in the experiment. This suggests TMP may have a stronger
interaction with GEN than with SMX.
The MACO scheme suggested TMP and GEN interacted
synergistically for inhibiting the bacterial growth. A sensitivity
analysis was thus performed to evaluate the activity between TMP
Figure 3. A 5-drug screening experiment using the MACO scheme. (a) Three concentration levels for each antibiotic are assigned. (b)
Fractional factorial experimental design for the five antibiotics. 18 experimental trials are required. (c) Bacterial growths with the antibiotic cocktails
described in (b). (d) Result of the regression analysis based on the factorial regression and quadratic response surface models.
SMX=sulphamethoxazole; CIN=cinnamon oil; PEP=peppermint oil.
doi:10.1371/journal.pone.0015472.g003
Figure 4. A 6-drug screening experiment. (a) Three concentration levels are assigned for each antibiotic. (b) The 18 experimental trials defined
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showed only a weak-to-moderate effect on the bacterial growth
without GEN. It is consistent with the fact that the MIC of TMP
for EC132 (i.e., 4 mg/ml) is much higher than the concentration
range tested in this experiment (0 to 0.5 mg/ml). When a small
amount of GEN is added, TMP displayed dose dependent
inhibitions on the bacterial growth. The effect of TMP was
significantly enhanced by GEN in a dose dependent manner. For
instance, the MIC of GEN could reduce to 0.1 mg/ml with
0.5 mg/ml of TMP and MIC of TMP could reduce to 0.1 mg/ml,
a 40-fold reduction, with 0.25 mg/ml of GEN. This supports that
TMP and GEN work synergistically and can significantly reduce
the MIC of the antibiotics. The synergistic activity of the cocktail
was then tested for several strains of uropathogenic E. coli clinical
isolates (Figure 5b). TMP alone only slightly reduced the bacterial
growth for all three strains of E. coli. Similarly, GEN alone at
0.25 mg/ml showed a negligible effect on the growth. It should be
noted that EC136 and EC137 are sensitivity to GEN at a higher
concentration. With the combination of TMP and GEN at the
same concentration, total inhibition of the bacteria growth was
observed for all three strains of uropathogenic E. coli. These results
indicate that TMP and GEN exhibit a strong synergistic
interaction and that this interaction is applicable to various strains
of E. coli.
Discussion
With the MACO scheme that chooses experimental trails
selectively and analyzes the data systematically, synergistic
antimicrobial cocktails can be quickly determined. Interestingly,
the MACO scheme identified the synergistic interaction between
TMP and GEN in this study. The mechanistic connection
between TMP and GEN at the molecular level is not obvious.
TMP inhibits the folate synthesis pathway by interfering the action
of bacterial dihydrofolate reductase and GEN inhibits protein
synthesis by distorting the structure of the ribosome-RNA
complex. This highlights the difficulty of predicting synergistic
cocktails by studying them individually and the importance of a
systematic approach for identifying synergistic antimicrobial
cocktails. The result in this study could provide an insightful
starting point for investigating the molecular mechanisms
responsible for this synergy [31,32]. While conventional antibiotic
screening focuses on molecular targets one at a time, the MACO
approach may lead to a viable pathway for identifying molecules
that can be targeted simultaneously for synergistic effects. On the
other hand, rapid identification of synergistic cocktails will directly
impact the management of bacterial infection. As discussed, high
doses of GEN are known to be toxic to the kidney and ears of the
host. In fact, GEN typically requires administration by body
weight and monitoring of the serum gentamicin level during
treatment. Using combination antimicrobial therapy, the MIC of
GEN can be reduced for 10-fold with a small amount of TMP.
This further supports the appealing nature of combination
therapy, which provides effective treatment with minimal toxicity
and side effects to the patient.
Optimizing a drug cocktail based on trial and error or clinical
empiricism is a challenging task, as evidenced by the time required
for developing combination therapies for various diseases. Since
the number of possible drug combinations is practically unlimited,
a systematic approach for rapidly identifying the most promising
cocktails and prioritizing their evaluation is critical. This study
demonstrated that potent antimicrobial cocktails could be
systematically determined using the MACO scheme. Our result
showed the robustness of the procedures of MACO, which
consistently identified the synergistic cocktails from different drug
combinations. An important advantage of the MACO scheme is
the simplicity of the approach that allows the dramatic reduction
in the number of experiment trails. The MACO scheme can be
easily accessible to researchers with standard microbiology
equipments and commercial statistic software. In this study, rapid
identification of a potent antimicrobial cocktail was demonstrated
from over seven hundred possible combinations in the antimicro-
bial search space. If the number of antibiotics increases to 13, a full
factorial design will require 1,594,323 (3
13) trials while the
fractional factorial design can reduce the number of trial to 27
only.
In addition to identifying novel antimicrobial cocktails for
building the next generation antibiotic pipeline in a large-scale
pharmaceutical facility, the MACO scheme will also be applicable
for clinical management of rapidly spreading in non-traditional
settings as a temporary clinic or even in the battlefield. Generally,
optimization of complex systems is a fruitful area in engineering,
computer science, and operational research. A particular optimi-
zation scheme may be uniquely suitable for a specific biomedical
problem. For example, search algorithms, such as Gur Game and
hill-climbing, were previously demonstrated for searching antiviral
and anticancer drugs from large parametric spaces. A major
difference between these search algorithms and MACO is that
stochastic search algorithms are sequential search methods (i.e.,
Figure 5. Synergistic activity of TMP and GEN. (a) In the sensitivity
analysis of the TMP-GEN cocktails, the dose dependence of TMP on the
bacterial growth with different concentration of GEN (in mg/ml) is
determined. (b) The antimicrobial cocktail with TMP (0.25 mg/ml) and
GEN (0.25 mg/ml) were tested for its individual and interaction effects.
The values of EC 132 and EC 137 were not observable in the graph due
to the low optical density.
doi:10.1371/journal.pone.0015472.g005
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in MACO can be operated in parallel. This presents a critical
advantage for timely management of rapidly spreading infectious
agents in clinical and biodefense settings. The small number of
experimental trials in MACO can be easily performed manually or
by a laboratory-scale robot at the point of care. In fact, it is
possible to perform rapid pathogen identification and antimicro-
bial susceptibility testing in 2–3 hours in resource limited settings
[33,34,35,36] and the MACO analysis can be easily implemented
in a laptop computer with commercially available software
packages. In summary, the effectiveness and simplicity of MACO
renders its potential for rapidly screening synergistic drug cocktails
toward the treatment of various diseases in the future.
Materials and Methods
Bacterial culture and reagents
Uropathogenic E. coli strains EC132, EC136, and EC137 were
used as model systems in this study. The pathogens were isolated
from clinical urine samples of patients with urinary tract infection
as part of a research protocol approved by the Institutional Review
Board at Stanford University. Six antibiotics, trimethoprim
(TMP), ampicillin (AMP), gentamicin (GEN), sulfamethoxazole
(SMX), cinnamon oil (CIN), and peppermint oil (PEP), were
considered in this study. EC132 has been tested for its
susceptibility to all six antibiotics and is resistant to AMP and
SMX [35,36]. The minimum inhibitory concentrations (MIC) of
TMP, GEN, PEP and CIN for EC132 are 4 mg/ml, 1 mg/ml,
0.08% and 0.08% (v/v) respectively. EC137 is sensitive to AMP,
GEN, and SMX and EC136 is resistant to AMP. The bacteria
colonies were carried on agar plates.
Antibiotic susceptibility testing (AST)
Before the experiment, the pathogens were cultured in Mueller-
Hinton broth in a flask in an orbital shaker at 37uC. After the
pathogens were grown to an early exponential phase with an
optical density (OD) between 0.2 and 0.6, they were diluted to OD
0.02 with Mueller Hinton broth with the appropriate antimicro-
bial cocktails, which were freshly prepared before each exper-
iment. The pathogens were then inoculated at 300 rpm and 37uC.
The concentrations of bacteria were determined using a micro-
volume spectrophotometer (Nanodrop 2000). Unless otherwise
specified, data represent absorbance 6 standard deviation
obtained from 4 independent measurements. The quantitative
bacterial concentration data were inputed to the statistic program
(STATISTICA 9.0, Statsoft Inc) for data analysis. Antimicrobial
susceptibility testing was performed using the same procedure to
test the synergistic effect of the antimicrobial cocktails. A pathogen
was considered to be sensitive to an antimicrobial cocktail if the
concentration of the pathogen is less than 10% of the control value
in our experiment.
Fractional factorial design
The MACO scheme is a systematic method for determining
potent antimicrobial cocktails. A pathogen of interest, such as a
clinical isolate or a biological warfare agent, was first selected.
Then, the concentrations (levels) of a set of antibiotics (indepen-
dent variables) were chosen. To focus on identifying antimicrobial
cocktails with synergistic activities, the concentration could be
selected to be below the typical minimum inhibitory concentration
(MIC) of the antibiotic. In such a situation, the individual effects of
antibiotics would unlikely be significant at low concentrations. A
fractional factorial design, which selected tests with input
parameter values capturing the individual and interactive effects
of the drug combinations, was generated using software package.
For 3 antibiotics each with 3 concentrations, 9 experimental trials
were required out of 27 (3
3) possible combinations. The reduction
in experimental trials increased rapidly with the number of
antibiotics being considered. For instance, only 18 trials is required




Experiment trials were performed based on the fractional
factorial design in the orthogonal matrix. The experimental data
were analyzed using two regression model designs: factorial
regression and quadratic response surface regression, since using
multiple regressing models could improve the robustness of the
analysis. In factorial regression analysis, main factors and
interaction effects were both considered. For three drugs (e.g.,
TMP, AMP, GEN), the coefficients for three main effects (TMP,
AMP, and GEN) and four interactions (TMP6AMP,
TMP6GEN, AMP6GEN, and TMP6AMP6GEN) were deter-
mined. Quadratic response surface regression is similar to factorial




were also considered in the analysis. The inclusion of the quadratic
response surface regression model will improve the ability of the
MACO scheme to capture non-linear effects of the antibiotics.
The data were analysis using a forward stepwise regression model-
building technique to identify the factors responsible for the
synergistic activity. The essences of stepwise regression are to
eliminate unnecessary elements and include only factors that have
significant effects on the overall response [21]. In this study, a
regression analysis is considered to be valid only when both
regression models converged to the same result. The stepwise
regression analysis was implemented using STATISTICA 9.0
(Statsoft Inc).
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